Galena Biopharma to Present at Two Upcoming Healthcare Investment Conferences

PORTLAND, Ore., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. GALE, a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer, will present a corporate update at two upcoming healthcare investment conferences:

Rodman & Renshaw 17th Annual Global Investment Conference
Wednesday, September 9, 2015 at 10:25 a.m. ET
St. Regis Hotel, New York, NY

NewsMakers in the Biotech Industry
Thursday, September 10, 2015 at 11:30 a.m. ET
Millennium Broadway Hotel, New York, NY

The presentations will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.

About Galena Biopharma

Galena Biopharma, Inc. GALE is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax™ (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz® (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information, visit www.galenabiopharma.com.